Novocure Ltd (NVCR)

[jondoeuk]

You need to stop spread misleading information to fool investors.

What is misleading?

The future of collaboration looks dire after Merck digested Dr. Bosch's presentation.

Data were presented at ASCO, with the companies starting a pivotal trial in adjuvant melanoma this year, and both will rapidly expand trials to additional solid tumours, including NSCLC https://www.accesswire.com/759236/Moderna-and-Merck-Announce-mRNA-4157-V940-in-Combination-With-KEYTRUDAR-pembrolizumab-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma

DCVax-L can be loaded with hundreds of tumor-specific antigens.

If a mutation is never transcribed, translated and processed, it cannot stimulate an immune response from T-cells. Looking at the data from Dr Rosenberg's group at the US NCI, as well as others, only approximately 1-2% of the mutations are actually transcribed, translated and processed, presented on the surface and can be recognised by the patient's own T-cells. So, identification for that and other reasons is very important.

DCVax-L can trigger immune memory which prevents recurrence.

The vaccine is an expensive placebo.

The clinical results from mRNA are mediocre as indicated by the Moderna SP.

MRNA's SP is over $127 vs. NWBO's at $0.66